Fig. S2



Fig. S2. BAD serine 134 plays a minor role regarding cell growth in RAS mutant and B-RAF/RAS wild type tumor cells. The tumor cell line HCT 116 that harbors mutated RAS and the tumor cell line PC3 that carries neither a RAF nor RAS mutation were treated with the indicated kinase inhibitors. Cell growth, expression levels of endogenous BAD, its phosphorylation at serine 134 and actin were analyzed. The efficiency of the kinase inhibitors Wortmannin, Sorafenib or PD0325901 has been verified by change of Akt serine 473 and ERK phosphorylation, respectively. Results obtained with RAS mutant tumor cell lines MEL-Juso and DX3 were analogous to results gained with HCT 116 cells (data not shown).